Edmund Y. Ting Ph.D., Sc.D. Ph.D.
Net Worth

Last updated:

What is Edmund Y. Ting Ph.D., Sc.D. Ph.D. net worth?

The estimated net worth of Dr. Edmund Y. Ting Ph.D., Sc.D. Ph.D. is at least $4,156,250 as of 22 Dec 2014. He has received compensation worth at least $4,156,250 in Pressure BioSciences, Inc..

What is the salary of Edmund Y. Ting Ph.D., Sc.D. Ph.D.?

Dr. Edmund Y. Ting Ph.D., Sc.D. Ph.D. salary is $218,750 per year as Senior Vice President of Engineering in Pressure BioSciences, Inc..

How old is Edmund Y. Ting Ph.D., Sc.D. Ph.D.?

Dr. Edmund Y. Ting Ph.D., Sc.D. Ph.D. is 70 years old, born in 1955.

What stocks does Edmund Y. Ting Ph.D., Sc.D. Ph.D. currently own?

As insider, Dr. Edmund Y. Ting Ph.D., Sc.D. Ph.D. owns shares in one company:

Company Title Shares Price per share Total value
Pressure BioSciences, Inc. (PBIO) Senior Vice President of Engineering 614 $0 $0

What does Pressure BioSciences, Inc. do?

Pressure BioSciences, Inc. develops and sells pressure-based platform solutions in the North America, Europe, and Asia. The company's pressure cycling technology (PCT) technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, including cells and tissues from human, animal, plant, and microbial sources. It offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB880, Barocycler HUB440, and The Shredder SG3. The company also distributes cell disruption equipment, parts, and consumables. In addition, it offers Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, PCT-Micro Pestle, and pressure used to lyse samples for extraction tubes, as well as application specific kits, including consumable products and reagents. The company serves researchers at academic laboratories, government agencies, biotechnology companies, pharmaceutical firms, and other life science institutions. It has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; Steinbeis Centre for biopolymer analysis and biological mass spectrometry; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. Pressure BioSciences, Inc. was incorporated in 1978 and is based in South Easton, Massachusetts. As of August 2, 2022, Pressure BioSciences, Inc. operates as a subsidiary of Emergent Health Corp.

Edmund Y. Ting Ph.D., Sc.D. Ph.D. insider trading

Pressure BioSciences, Inc.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock Warrant 5,220 N/A N/A
Purchase
Series G Convertible Preferred Stock 614 N/A N/A
Purchase
Series G Common Stock Purchase Warrant 3,070 N/A N/A
Option
Series A Convertible Preferred Stock 160 N/A N/A
Option
15-Month Preferred Stock Purchase Warrant 522 N/A N/A
Purchase
30-Month Common Stock Purchase Warrant 5,220 N/A N/A
Purchase
Series A Convertible Preferred Stock 522 N/A N/A
Purchase
Common Stock, $0.01 par value 2,000 N/A N/A

Pressure BioSciences key executives

Pressure BioSciences, Inc. executives and other stock owners filed with the SEC: